IRLAB’s Phase IIb Study with Pirepemat Passes DSMB Safety Review with Unanimous Recommendation to Continue the Ongoing Phase IIb Study

GOTHENBURG, SWEDEN / ACCESSWIRE / July 17, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 17, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's …